287 related articles for article (PubMed ID: 14634775)
1. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
2. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue.
Broll R; Duchrow M; Oevermann E; Wellm C; Schwandner O; Schimmelpenning H; Roblick UJ; Bruch HP; Windhövel U
Int J Colorectal Dis; 2001 Feb; 16(1):22-7. PubMed ID: 11317693
[TBL] [Abstract][Full Text] [Related]
3. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Ootani K; Yasuda K; Murono K; Watanabe T
Oncology; 2017; 92(1):31-38. PubMed ID: 27794579
[TBL] [Abstract][Full Text] [Related]
5. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters.
Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L
Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964
[TBL] [Abstract][Full Text] [Related]
6. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
7. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer.
Hammel P; Leroy-Viard K; Chaumette MT; Villaudy J; Falzone MC; Rouillard D; Hamelin R; Boissier B; Remvikos Y
Int J Cancer; 1999 May; 81(5):712-8. PubMed ID: 10328221
[TBL] [Abstract][Full Text] [Related]
8. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
[TBL] [Abstract][Full Text] [Related]
9. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
Shimizu K; Ueda Y; Yamagishi H
Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
[TBL] [Abstract][Full Text] [Related]
10. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T
Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Nozawa H; Ishihara S; Kawai K; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Watanabe T
Oncology; 2016; 91(3):127-34. PubMed ID: 27362767
[TBL] [Abstract][Full Text] [Related]
14. Stereologic estimates of volume-weighted mean nuclear volume in colorectal adenocarcinoma: correlation with histologic grading, Dukes' staging, cell proliferation activity and p53 protein expression.
Martín R; Nieto S; Santamaría L
Gen Diagn Pathol; 1997 Jul; 143(1):29-38. PubMed ID: 9269906
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
16. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
17. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
[TBL] [Abstract][Full Text] [Related]
18. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
[TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection.
Takeda A; Shimada H; Nakajima K; Yoshimura S; Suzuki T; Asano T; Ochiai T; Isono K
Int J Clin Oncol; 2001 Feb; 6(1):45-9. PubMed ID: 11706527
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
